Tenax Therapeutics, Inc., a specialty pharmaceutical company, is dedicated to identifying, developing, and marketing products for cardiovascular and pulmonary disease in the United States and Canada. The company is headquartered in Morrisville, North Carolina.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-19.49M |
| Operating Margin | 0.00% |
| Return on Equity | -55.60% |
| Return on Assets | -35.10% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $2.29 |
| Price-to-Book | 2.64 |
| Price-to-Sales (TTM) | 414.72 |
| EV/Revenue | 263.34 |
| EV/EBITDA | -0.14 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $17.20M |
| Float | $17.17M |
| % Insiders | 0.11% |
| % Institutions | 46.32% |
Volatility is currently contracting